Neutralizing anti-influenza B antibodies and uses thereof

US12325740B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• Humabs BioMed SA · CH

Inventors

• Nicole Kallewaard-Lelay · Gaithersburg, US
• Qing Zhu · Mansfield Center, US
• Ebony Benjamin · Gaithersburg, US
• Leslie Wachter · Gaithersburg, US
• Andy Yuan · Gaithersburg, US
• Josephine Mary McAuliffe · Gaithersburg, US
• Davide Corti · Bellinzona, CH
• Antonio Lanzavecchia · Bellinzona, CH

Key dates

• Filing date: Sep 8, 2023
• Grant date: Jun 10, 2025
• Expiry date: Sep 8, 2043

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.